ACUTE MYELOID LEUKEMIA

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remi…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…

This phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…

This phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …

This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…

This study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…

This study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted drug (quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo helps control the cancer. About 52…

This phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …

This early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has re…

This study tests whether the immunotherapy drug nivolumab can wipe out any leftover leukemia cells and prevent the cancer from returning in people with acute myeloid leukemia (AML) who are already in remission after chemotherapy. The trial enrolled 82 adults whose AML had respond…

This study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…

This study aims to find the safest and most effective initial chemotherapy for older adults (60-75) newly diagnosed with acute myeloid leukemia who can handle strong treatment. About 90 participants will be randomly assigned to one of two drug combinations or a standard treatment…

This early-phase trial is testing whether adding a drug called iadademstat to the standard combination of venetoclax and azacitidine is safe and tolerable for adults with untreated acute myeloid leukemia (AML). About 45 people with intermediate- or high-risk AML will take part. T…

This trial aimed to test the drug ASTX727 (Inqovi) alone or with donor immune cells in people with blood cancers who had a stem cell transplant. The goal was to see if it could control cancer that remained or came back. However, the study was withdrawn before enrolling any patien…

This early-phase study tests a new three-drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment includes a targeted radiation antibody (lintuzumab-Ac-225) plus two oral drugs (venetoclax and ASTX-727).…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This phase 2 trial tests whether a combination of two drugs, venetoclax (a pill) and azacitidine (an infusion), works better than standard intensive chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). The study enrolls 172 fit adults and measures how long t…

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants …

This early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…

This study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to s…

This phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…

This early-phase trial tests a combination of two drugs—entrectinib and ASTX727—in people with a specific, hard-to-treat form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study aims to find the safest dose and watch for side effects in 13 a…

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…

This phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…

This phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA me…

This phase 2 trial tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can improve outcomes for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls 116 adults aged 18-70 who have a matche…

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…

This study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…

This study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has returned or not responded to treatment. The goal is to see if the combination is safe and can help co…

This phase 2 study tests whether the drug ruxolitinib can help prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a stem cell transplant. About 64 older adults in remission will take ruxolitinib as maintenance therapy. The goal is to see…

This early-stage trial tests the safety and best dose of combining two drugs—everolimus and midostaurin—for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is hard to treat. The drugs work by blocking faulty signals that help cance…

This phase 2 trial tests a combination of chidamide, azacytidine, and a chemotherapy regimen (HAG) in 21 adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see how well the combo works and what side effects it causes. Participants …

This early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…

This early-phase trial tests a drug called CRD3874-SI, which activates the STING protein to help the immune system attack cancer cells. It is for adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the r…

This phase 3 trial tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special mix of stem cells and immune cells from a matched donor, designed to reduce a serious side effect called graft-versus-host disease. The study compares …

This early-phase study tests the safety of combining venetoclax with decitabine in 26 adults with high-risk acute myeloid leukemia (AML). Participants have hard-to-treat forms of the disease, such as relapsed or genetically complex AML. The goal is to find the best dose and under…

This study tests whether adding a drug called selinexor to standard chemotherapy can help children with a specific, high-risk form of acute myeloid leukemia (NUP98-positive AML). Ten children will receive the combination during their first two rounds of treatment. The goal is to …

This early-phase study tests whether the drug talazoparib can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a specific genetic mutation (cohesin) and cannot receive standard intensive chemotherapy. The main goal is to see if the drug red…

This early-stage trial is testing an experimental pill called BMF-500 in 35 adults with acute leukemia, especially those with a specific genetic mutation (FLT3). The main goals are to check the drug's safety, find the right dose, and see if it can help control the disease. Partic…

This Phase 1 trial aimed to test whether bone marrow from deceased, mismatched unrelated donors could be safely used for transplants in patients with blood cancers like leukemia. The approach used stored (cryopreserved) marrow along with drugs to prevent rejection. However, the s…

This study tests whether a geriatric assessment—looking at thinking, mobility, mood, nutrition, and medications—can help doctors choose the right transplant intensity for patients aged 60 and older with myeloid blood cancers. The goal is to reduce deaths from transplant complicat…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This early-phase trial tests a precise radiation technique called total marrow/lymphoid irradiation (TMLI) combined with the chemotherapy drug cyclophosphamide for people with acute myeloid leukemia in remission. The goal is to see if this approach is safe and can help prepare th…

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia (AML) who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefit outweighs the risks. The drug is …

This study tests whether taking an oral chemotherapy drug (azacitidine) as maintenance therapy can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older who are already in remission. Participants will receive either the drug or a placebo, al…

This early-phase trial tests whether infusing specially grown donor immune cells (gamma delta T-cells) can prevent acute myeloid leukemia from returning in patients who are at high risk of relapse after a stem cell transplant. About 20 adults aged 18–75 will receive a single infu…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that can control the disease. Sixteen adults aged 18 and older a…

This study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome. Instead of radiating the whole body, the new method targets only the bone marrow and lymph nodes, which may reduce damage to healthy organs. The goa…

This phase II trial tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant in adults with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free s…

This study tests whether adding the drug uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants will receive either chemo alone or chemo plus uproleselan. The goal is to see if the…

This study follows about 100 adults with acute myeloid leukemia (AML) who are already prescribed venetoclax by their doctors in Israel. Researchers will track how long patients live and how many achieve remission during routine care. The goal is to understand the drug's real-worl…

This program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.

This study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine after they finished a previous trial. The main goal is to track any side effects and see how safe the drug is over a longer period. Abo…

This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 38 adults aged 18–65 will receive the com…

This early-phase trial tests a new drug called tegavivint, given together with the chemotherapy decitabine, for people whose leukemia has returned or not responded to standard treatments. The main goals are to find the safest dose and to watch for side effects. Only 9 adults with…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This early-phase trial tests a combination of two treatments for people whose myeloid blood cancer (like AML or MDS) has returned after a matched stem cell transplant. The treatments are a specially processed donor immune cell infusion and an immunotherapy drug called ipilimumab.…

This study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…

This early-stage study tests a new approach for people with acute myeloid leukemia (AML) that has returned or is likely to return, and who cannot have a bone marrow transplant. Researchers take a patient's own leukemia cells, modify them in the lab to produce a protein called IL-…

This study looks at how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 210 people across Canada will take venetoclax pills daily as part of their normal care. Researchers will track their overall survival a…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests whether a combination of two oral medications (ASTX727 and venetoclax) can work as well as standard intravenous chemotherapy for younger adults (ages 18-65) with a high-risk form of acute myeloid leukemia (AML). The goal is to find a safe, effective dose and see …

This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to monitor long-term safety. About 332 partici…

This phase II trial tests a new way to use cord blood transplants for people with high-risk acute leukemia or myelodysplasia. The cord blood is treated with a molecule called UM171 to increase the number of stem cells, which may help the transplant work better and reduce serious …

This early-phase trial tests whether specially trained immune cells from a donor can safely target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a stem cell transplant. The cells are grown in a lab to recognize four prot…

This study tests an experimental drug called galinpepimut-S (GPS) in adults with acute myeloid leukemia (AML) who are in remission after second-line treatment. The goal is to see if GPS can help keep the cancer from coming back longer than the best available standard treatments. …

This study tests the safety of a new drug called PRL3-ZUMAB in people with advanced solid tumors that have not responded to standard treatments. It is the first time this drug is given to humans, after showing promise in animal tests. The trial will enroll 38 participants and gra…

This early-phase trial tests a new type of cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack leukemia cells carrying…

This early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has returned or not responded to treatment. Researchers take a patient's own (or a donor's) T-cells, modify them in…

This study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …

This study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…

This study tests whether a high-intensity parenting program can improve learning and school functioning in Latino children being treated for leukemia or lymphoma. About 214 parents and children will take part. Parents in the high-intensity group will receive extra training in ski…

This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 patients receiving non-intensive therapy will take…

This study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more about the effects of treatment, not to…

This study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …

This study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…

This study tests whether a special PET/CT scan using a radioactive tracer called FLT can measure how well chemotherapy is working in people with newly diagnosed acute myeloid leukemia (AML). The scan lights up fast-growing cancer cells, and researchers want to see if it can predi…

This study looks at how quality of life differs among older adults (60+) newly diagnosed with acute myeloid leukemia (AML) who receive either intensive or non-intensive chemotherapy. Researchers aim to build a decision-making model that helps patients and doctors choose treatment…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at whether it is safe to wait before giving a second round of chemotherapy to adults newly diagnosed with acute myeloid leukemia (AML), even if a mid-treatment bone marrow biopsy shows some remaining disease. About 60 participants will receive standard first chem…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study is testing a new blood test called AlloHeme that measures how much of a patient's own cells remain after a bone marrow transplant. The goal is to see if this test can predict whether the cancer (acute leukemia or myelodysplastic syndrome) will come back. About 307 adul…

This early-phase study looks at how the immune system responds to leukemia tumors after low-dose radiation given as part of standard care. Ten adults with new or recurrent myeloid leukemia will have their immune responses measured. The goal is to learn whether adding immunotherap…

This study examines how adrenomedullin, a natural protein, affects leukemia stem cells in patients with acute myeloid leukemia (AML). Researchers will collect bone marrow and blood samples from 72 newly diagnosed AML patients to measure adrenomedullin levels and study its effects…

This study looks at whether testing cancer cells in a lab can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers will take blood and bone marrow samples before and during treatment to see if lab res…

This study looks at genetic changes in cancer stem cells from children and young adults with acute leukemia. Researchers will analyze bone marrow or blood samples to find gene patterns that may drive the disease. The goal is to better understand leukemia and potentially discover …

This study looks at whether a special type of testing, called leukemia profiling, can help find personalized treatment options for children and young adults up to age 30 with recurrent, refractory, or high-risk leukemias. Researchers analyze the genetic changes in each patient's …

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to un…

This study looks at whether checking for leftover leukemia-related gene mutations after initial chemotherapy can help predict relapse and survival in adults with acute myeloid leukemia (AML). Researchers will follow 107 patients aged 18-60 who are in remission after chemo. Those …

This study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…